164 related articles for article (PubMed ID: 20088801)
1. ROCK inhibitors as emerging therapeutic candidates for sarcomas.
Micuda S; Rösel D; Ryska A; Brábek J
Curr Cancer Drug Targets; 2010 Mar; 10(2):127-34. PubMed ID: 20088801
[TBL] [Abstract][Full Text] [Related]
2. Rho/ROCK signaling in motility and metastasis of gastric cancer.
Matsuoka T; Yashiro M
World J Gastroenterol; 2014 Oct; 20(38):13756-66. PubMed ID: 25320513
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of Rho/ROCK signaling in sarcoma cells drives invasion and increased generation of protrusive forces.
Rösel D; Brábek J; Tolde O; Mierke CT; Zitterbart DP; Raupach C; Bicanová K; Kollmannsberger P; Panková D; Vesely P; Folk P; Fabry B
Mol Cancer Res; 2008 Sep; 6(9):1410-20. PubMed ID: 18819929
[TBL] [Abstract][Full Text] [Related]
4. Metastasis of aggressive amoeboid sarcoma cells is dependent on Rho/ROCK/MLC signaling.
Kosla J; Paňková D; Plachý J; Tolde O; Bicanová K; Dvořák M; Rösel D; Brábek J
Cell Commun Signal; 2013 Jul; 11():51. PubMed ID: 23899007
[TBL] [Abstract][Full Text] [Related]
5. Plumbagin reduces osteopontin-induced invasion through inhibiting the Rho-associated kinase signaling pathway in A549 cells and suppresses osteopontin-induced lung metastasis in BalB/c mice.
Kang CG; Im E; Lee HJ; Lee EO
Bioorg Med Chem Lett; 2017 May; 27(9):1914-1918. PubMed ID: 28359791
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone.
Liu S; Goldstein RH; Scepansky EM; Rosenblatt M
Cancer Res; 2009 Nov; 69(22):8742-51. PubMed ID: 19887617
[TBL] [Abstract][Full Text] [Related]
7. Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.
Sadok A; McCarthy A; Caldwell J; Collins I; Garrett MD; Yeo M; Hooper S; Sahai E; Kuemper S; Mardakheh FK; Marshall CJ
Cancer Res; 2015 Jun; 75(11):2272-84. PubMed ID: 25840982
[TBL] [Abstract][Full Text] [Related]
8. Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.
Feng Y; LoGrasso PV; Defert O; Li R
J Med Chem; 2016 Mar; 59(6):2269-300. PubMed ID: 26486225
[TBL] [Abstract][Full Text] [Related]
9. Rho kinase inhibitors: potential treatments for diabetes and diabetic complications.
Zhou H; Li YJ
Curr Pharm Des; 2012; 18(20):2964-73. PubMed ID: 22571664
[TBL] [Abstract][Full Text] [Related]
10. Rho kinase inhibitors: a patent review (2012 - 2013).
Feng Y; LoGrasso PV
Expert Opin Ther Pat; 2014 Mar; 24(3):295-307. PubMed ID: 24283930
[TBL] [Abstract][Full Text] [Related]
11. Roles of Rho‑associated kinase in lung cancer (Review).
Zakaria MA; Rajab NF; Chua EW; Selvarajah GT; Masre SF
Int J Oncol; 2021 Feb; 58(2):185-198. PubMed ID: 33491756
[TBL] [Abstract][Full Text] [Related]
12. Rho-kinase as a therapeutic target in vascular diseases: striking nitric oxide signaling.
Kolluru GK; Majumder S; Chatterjee S
Nitric Oxide; 2014 Dec; 43():45-54. PubMed ID: 25196952
[TBL] [Abstract][Full Text] [Related]
13. Could pharmacological curtailment of the RhoA/Rho-kinase pathway reverse the endothelial barrier dysfunction associated with Ebola virus infection?
Eisa-Beygi S; Wen XY
Antiviral Res; 2015 Feb; 114():53-6. PubMed ID: 25512227
[TBL] [Abstract][Full Text] [Related]
14. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
Kolavennu V; Zeng L; Peng H; Wang Y; Danesh FR
Diabetes; 2008 Mar; 57(3):714-23. PubMed ID: 18083785
[TBL] [Abstract][Full Text] [Related]
15. ROCK inhibition promotes microtentacles that enhance reattachment of breast cancer cells.
Bhandary L; Whipple RA; Vitolo MI; Charpentier MS; Boggs AE; Chakrabarti KR; Thompson KN; Martin SS
Oncotarget; 2015 Mar; 6(8):6251-66. PubMed ID: 25749040
[TBL] [Abstract][Full Text] [Related]
16. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.
Knipe RS; Tager AM; Liao JK
Pharmacol Rev; 2015; 67(1):103-17. PubMed ID: 25395505
[TBL] [Abstract][Full Text] [Related]
17. X-ray irradiation and Rho-kinase inhibitor additively induce invasiveness of the cells of the pancreatic cancer line, MIAPaCa-2, which exhibits mesenchymal and amoeboid motility.
Fujita M; Otsuka Y; Yamada S; Iwakawa M; Imai T
Cancer Sci; 2011 Apr; 102(4):792-8. PubMed ID: 21214671
[TBL] [Abstract][Full Text] [Related]
18. Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression.
Borin TF; Arbab AS; Gelaleti GB; Ferreira LC; Moschetta MG; Jardim-Perassi BV; Iskander AS; Varma NR; Shankar A; Coimbra VB; Fabri VA; de Oliveira JG; Zuccari DA
J Pineal Res; 2016 Jan; 60(1):3-15. PubMed ID: 26292662
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of cell adhesion via rho-associated protein kinase (ROCK) pathway promotes tumor cell migration on laminin-511.
Kikkawa Y; Harashima N; Ikari K; Fujii S; Katagiri F; Hozumi K; Nomizu M
Exp Cell Res; 2016 May; 344(1):76-85. PubMed ID: 27068375
[TBL] [Abstract][Full Text] [Related]
20. HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways.
Nakabayashi H; Shimizu K
Cancer Sci; 2011 Feb; 102(2):393-9. PubMed ID: 21166955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
